Aktualności
EMA: Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products
22.03.2012
This reflection paper provides a critical review of the adequacy/appropriateness of risk mitigation measures included in current marketing authorisations of veterinary medicinal products. ...
GMP: New Requirements for the Submission of Information on Medicinal Products - EMA publishes New Guidance for MAHs and a revised \"Legal Notice\"
22.03.2012
The background to this catalogue of requirements is the provisions laid down in Article 57(2) of the new Regulation (EU) No 1235/2010. According to that regulation, the EMA requires these data to
...
GMP: Transitional Regulations for the New Pharmacovigilance Package: Commission\'s Q&A Document provides Clarity
15.03.2012
Several provisions for pharmacovigilance have been newly defined among others with Regulation (EU) No 1235/2010 and Directive 2010/84/EU from 2010. Marketing authorisation holders are now
...
GMP: FDA\'s new web-based Training explains FDA Drug Regulatory Work
15.03.2012
A new tool has been developed: the \"CDER World\", containing free e-learning modules with information about how CDER works. The respective modules deliver information based on the CDER
...
GMP: Regulatory Monitoring of API Manufacturers - FDA, TGA, EMA and EDQM express Common Objectives for Inspections Collaboration
15.03.2012
On 6 March 2012, the EMA published a paper entitled \"Programme to rationalise international GMP inspections of active pharmaceutical ingredient/active substances manufacturers - Terms of
...
EMA: Concept paper on the need for revision of the guideline on excipients in the label and package leaflet of medicinal products for human use (CPMP/463/00)
08.03.2012
The current guideline on Excipients in the Label and Package Leaflet of Medicinal Products for Human Use (CPMP/463/00) contains warning statements relating to the presence of certain excipients in
...
GMP: FDA - New draft guidances for Biosimilars
08.03.2012
On 9 February the US Food and Drug Administration published three draft guidance documents on the development of biosimilar products. The intention of these documents is to meet the demands of the
...
GMP: EMA Reflection Paper on Sourcing Biological Starting Materials
08.03.2012
After the FDA has recently published a draft Guidance on Monitoring Crude Heparin for Quality, the European Medicines Agency EMA has now drafted a Reflection Paper on the use of starting materials
...
EMA: Reflection paper on the use of starting materials and intermediates collected from different sources in the manufacturing of biological medicinal products
01.03.2012
In the European pharmaceutical legislation, requirements are outlined for particulars and documents that should accompany an application for marketing authorisation of a biological medicinal product. ...
EMA: Reflection paper on the necessity of initiatives to stimulate the conduct of clinical studies with herbal medicinal products in the paediatric population
01.03.2012
The aim of this document is to highlight the lack of clinical studies on the majority of herbal medicinal products in children and the need for initiatives to stimulate the conduct of clinical
...
